Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03575234
Title Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Recruitment Withdrawn
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Emory University
Indications

oral squamous cell carcinoma

oropharynx cancer

Therapies

Cyclophosphamide + IRX-2 + Nivolumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.